Advertisement

Charles M. Rudin, MD, PhD

Articles

Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

July 29th 2022

The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

July 29th 2022

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.

Ongoing Trials and Real-World Studies in Frontline SCLC

July 18th 2022

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

July 18th 2022

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

July 11th 2022

Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.

Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

July 6th 2022

Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.

Progress in the Treatment and Management of SCLC

July 6th 2022

The panel discusses how the field of small cell lung cancer treatment has changed in recent years.

Use of the TNM Staging System in SCLC

June 27th 2022

Charles Rudin, MD, PhD, explains the prognostic staging systems used for small cell lung cancer.

Overview of SCLC and Importance of Early Diagnosis

June 27th 2022

Drs Owonikoko and Weiss provide a brief overview of small cell lung cancer and the vital importance of an early diagnosis to improve patient outcomes.

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

July 9th 2020

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Dr. Rudin on Expansion of Immunotherapy in Lung Cancer

August 8th 2019

Charles M. Rudin, MD, PhD, the Sylvia Hassenfeld Chair in Lung Cancer Research, chief, Thoracic Oncology, co-director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the current landscape of immunotherapy in lung cancer and how he expects the treatment to expand.

Dr. Rudin Discusses the Success of Immunotherapy in SCLC

October 30th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

Dr. Rudin on Immunotherapy Biomarkers in Lung Cancer

April 25th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Dr. Rudin on Significance of the KEYNOTE-021 in Patients With NSCLC

April 17th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Advertisement
Advertisement